Pharsight

Orbactiv patents expiration

ORBACTIV's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8420592 MELINTA THERAP Methods of treatment using single doses of oritavancin
Aug, 2029

(5 years from now)

US9682061 MELINTA THERAP Methods of treating bacterial infections using oritavancin
Apr, 2030

(6 years from now)

US9649352 MELINTA THERAP High purity oritavancin and method of producing same
Jul, 2035

(11 years from now)

Orbactiv is owned by Melinta Therap.

Orbactiv contains Oritavancin Diphosphate.

Orbactiv has a total of 3 drug patents out of which 0 drug patents have expired.

Orbactiv was authorised for market use on 06 August, 2014.

Orbactiv is available in powder;intravenous dosage forms.

Orbactiv can be used as treatment of bacterial skin and skin structure infections, treatment of bacterial skin and skin structure infections using a single dose.

Drug patent challenges can be filed against Orbactiv from 2023-08-07.

The generics of Orbactiv are possible to be released after 16 July, 2035.

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Aug 6, 2019
Generating Antibiotic Incentives Now (GAIN) Aug 6, 2024

Drugs and Companies using ORITAVANCIN DIPHOSPHATE ingredient

NCE-1 date: 2023-08-07

Market Authorisation Date: 06 August, 2014

Treatment: Treatment of bacterial skin and skin structure infections using a single dose; Treatment of bacterial skin and skin structure infections

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

ORBACTIV family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic